Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.820
+0.030 (1.06%)
Apr 21, 2026, 4:08 PM HKT
Market Cap7.25B +4.1%
Revenue (ttm)763.16M -3.3%
Net Income-175.20M
EPS-0.17
Shares Out1.04B
PE Ration/a
Forward PEn/a
Dividend0.03 (1.14%)
Ex-Dividend DateJul 10, 2025
Volume789,000
Average Volume1,743,900
Open2.850
Previous Close2.820
Day's Range2.810 - 2.900
52-Week Range2.330 - 5.290
Beta0.19
RSI41.42
Earnings DateMar 30, 2026

About HKG:1349

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and H... [Read more]

Sector Healthcare
Founded 1996
Employees 899
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1349
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements